Renal cancer is a common malignant
tumor in
urology, with complicated pathogenesis and no obvious clinical symptoms. Metastatic
renal cancer accounts for 20%-30% of the newly diagnosed
renal cancer. The 5-year
survival rate for metastatic
patients is less than 10%.At present, the main non-surgical
treatment means of mRCC include
cytokines and targeted
drug therapy, and
immunotherapy has also become a
research hotspot of mRCC. The current status and
research progress of mRCC
therapy were reviewed. The medical
treatment methods of metastatic
renal cancer, such as receptor
tyrosine kinase inhibitors and
mTOR inhibitors;
immunotherapies, such as
immunosuppressants for PD-1/PD-L1 were also discussed.